Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|July 2, 2016
- Pharmaceutical Technology-07-02-2016
- Volume 40
- Issue 7
Data Integrity Solution Improves Quality and Compliance
The LabX from Mettler Toledo has the ability to connect different laboratory instruments to one management system.
The LabX from Mettler Toledo has the ability to connect different laboratory instruments to one management system. This ability to connect and archive data assists in eliminating administrative bottlenecks and the risk of transcription and recalculation error in manual processing. LabX helps to ensure that all data produced by lab equipment meet fundamental quality elements and criteria for scientific soundness to meet GMP 21 CFR 211. By allowing analytical instruments to send data electronically, the process of data generation, plausibility checks, and data transfer is automated. LabX provides automatic results evaluation and stores complete data sets, including meta data for later reference and use.
Articles in this issue
about 10 years ago
FDA and Manufacturers Intensify Concerns about Data Integrityabout 10 years ago
Planning a Biologics Facility Start Upabout 10 years ago
Solid-Dosage Packaging Trendsabout 10 years ago
Quality System for a Regulatory Affairs Departmentabout 10 years ago
Data Integrity Challenges in Manufacturingabout 10 years ago
Bio/Pharma Funding Challenges Could Hurt CDMOs in 2017about 10 years ago
Cleaning Bioreactors and Fermenters with CIP Systemsabout 10 years ago
Maximize Efficiency in Tooling Maintenanceabout 10 years ago
Recognizing Pharma Industry Excellenceabout 10 years ago
Expanding the Chiral ToolboxRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5